Evidence map›Paper›PMID 27531881›Full record

ReviewOral oncology2016

The other side of the coin: Leveraging Epstein-Barr virus in research and therapy.

Fenggang Yu, Wei Jian Tan, Yanan Lu, Paul A MacAry, Kwok Seng Loh

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oral oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fenggang YuDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: entyf@nus.edu.sg.
Wei Jian TanDepartment of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Yanan LuDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Paul A MacAryDepartment of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Kwok Seng LohDepartment of Otolaryngology-Head and Neck Surgery, National University Health System, Singapore.
National University of Singapore · SGNational University Health System · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research efforts primarily focused on dissecting the mechanism of EBV-induced oncogenesis. Here, we present an alternate facet of the oncovirus EBV, on its applications in research and therapy. Finally, discussions on the prospective utilization of EBV in nasopharyngeal carcinoma (NPC) diagnosis and therapy will also be presented.

Indexed as

Genetic TherapyGenetic VectorsHerpesvirus 4, HumanHumansImmunotherapyLymphomaNasopharyngeal NeoplasmsEpstein-Barr virusLymphomaNasopharyngeal carcinomaResearch and therapy

Identifiers

PMID27531881
PMCPMC7108324
OpenAlexW2493547144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.